[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20100521T1 - Monoklonska antitijela protiv čimbenika rasta hepatocita - Google Patents

Monoklonska antitijela protiv čimbenika rasta hepatocita Download PDF

Info

Publication number
HRP20100521T1
HRP20100521T1 HR20100521T HRP20100521T HRP20100521T1 HR P20100521 T1 HRP20100521 T1 HR P20100521T1 HR 20100521 T HR20100521 T HR 20100521T HR P20100521 T HRP20100521 T HR P20100521T HR P20100521 T1 HRP20100521 T1 HR P20100521T1
Authority
HR
Croatia
Prior art keywords
hgf
monoclonal antibody
mab
inhibits
binding
Prior art date
Application number
HR20100521T
Other languages
English (en)
Croatian (hr)
Inventor
Jin Kim Kyung
Su Yi-Chi
Original Assignee
Galaxy Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100521(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galaxy Biotech filed Critical Galaxy Biotech
Publication of HRP20100521T1 publication Critical patent/HRP20100521T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HR20100521T 2004-04-15 2010-09-22 Monoklonska antitijela protiv čimbenika rasta hepatocita HRP20100521T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/825,060 US20040208876A1 (en) 2003-04-18 2004-04-15 Monoclonal antibodies to hepatocyte growth factor
PCT/US2004/026565 WO2005107800A1 (en) 2004-04-15 2004-08-13 Monoclonal antibodies to hepatocyte growth factor

Publications (1)

Publication Number Publication Date
HRP20100521T1 true HRP20100521T1 (hr) 2010-10-31

Family

ID=35320045

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100521T HRP20100521T1 (hr) 2004-04-15 2010-09-22 Monoklonska antitijela protiv čimbenika rasta hepatocita

Country Status (26)

Country Link
US (5) US20040208876A1 (ja)
EP (2) EP1734995B1 (ja)
JP (2) JP4594381B2 (ja)
KR (1) KR101072736B1 (ja)
CN (1) CN1964738A (ja)
AT (1) ATE473760T1 (ja)
AU (1) AU2004319276C1 (ja)
BR (1) BRPI0418745A (ja)
CA (1) CA2563080C (ja)
CR (1) CR8698A (ja)
CY (1) CY1110783T1 (ja)
DE (1) DE602004028168D1 (ja)
DK (1) DK1734995T3 (ja)
ES (1) ES2346886T3 (ja)
HK (1) HK1094167A1 (ja)
HR (1) HRP20100521T1 (ja)
IL (1) IL178474A (ja)
MX (1) MXPA06011822A (ja)
NO (1) NO20065227L (ja)
NZ (1) NZ550324A (ja)
PL (1) PL1734995T3 (ja)
PT (1) PT1734995E (ja)
RU (1) RU2361879C2 (ja)
SI (1) SI1734995T1 (ja)
WO (1) WO2005107800A1 (ja)
ZA (1) ZA200609407B (ja)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
JP5068651B2 (ja) * 2004-08-05 2012-11-07 ジェネンテック， インコーポレイテッド ヒト化抗ｃｍｅｔ抗体
US20070036797A1 (en) * 2005-06-02 2007-02-15 Galaxy Biotech, Llc Methods of treating brain tumors with antibodies
WO2007043641A1 (ja) 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
CN101330930B (zh) 2005-10-21 2011-11-23 中外制药株式会社 心脏病治疗剂
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
JPWO2007061029A1 (ja) * 2005-11-25 2009-05-07 学校法人慶應義塾 前立腺癌治療剤
AR059213A1 (es) 2006-01-27 2008-03-19 Univ Keio Agentes terapeuticos para enfermedades que involucran neovascularizacion coroidal
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CN101495146B (zh) 2006-04-07 2012-10-17 国立大学法人大阪大学 肌肉再生促进剂
NZ573819A (en) * 2006-06-02 2011-09-30 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
PL2027156T3 (pl) 2006-06-02 2011-06-30 Aveo Pharmaceuticals Inc Białka wiążące czynnik wzrostowy hapatocytów (HGF)
RU2450829C2 (ru) 2007-01-23 2012-05-20 Синсу Юниверсити Ингибитор хронического отторжения
MX2009013886A (es) * 2007-06-25 2010-01-27 Amgen Inc Composiciones de agentes de aglutinacion especifica al factor de crecimiento de los hepatocitos.
CL2009000843A1 (es) * 2008-04-11 2009-07-24 Galaxy Biotech Llc Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
US20110104161A1 (en) * 2008-05-14 2011-05-05 Burgess Teresa L Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
CN104906581A (zh) 2008-06-05 2015-09-16 国立研究开发法人国立癌症研究中心 神经浸润抑制剂
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20120052064A1 (en) * 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
CN101555912B (zh) * 2009-04-29 2012-10-03 深圳市特辰科技股份有限公司 一种转轮式自锁安全制动装置及其工作方法
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
CA2812744A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
TW201306866A (zh) 2011-06-30 2013-02-16 Genentech Inc 抗－ｃ－ｍｅｔ抗體調配物
CZ303636B6 (cs) * 2011-08-19 2013-01-23 Invos, Spol. S R. O. Biokontejner pro sber bioodpadu a komunálního odpadu
EP2753357A1 (en) 2011-09-09 2014-07-16 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
US9201074B2 (en) 2011-09-20 2015-12-01 Eli Lilly And Company Anti-c-Met antibodies
WO2014010586A1 (ja) 2012-07-10 2014-01-16 武田薬品工業株式会社 注射用製剤
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
EP2964673A4 (en) * 2013-03-14 2017-02-22 Alder Biopharmaceuticals, Inc. Antibodies to hgf and compositions containing
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US722041A (en) * 1902-11-24 1903-03-03 Mail Belting Company Conveyer-belt.
JP2564486B2 (ja) 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
GB9003621D0 (en) 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
JP2000515735A (ja) * 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
AU5588099A (en) 1998-08-28 2000-03-21 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
WO2003010282A2 (en) 2001-07-26 2003-02-06 Eli Lilly And Company Interleukin-1 beta antibodies
CA2472383A1 (en) 2001-12-27 2003-07-17 Van Andel Research Institute Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
WO2004019991A2 (en) * 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
KR101148657B1 (ko) 2003-06-06 2012-07-05 제넨테크, 인크. Ｈｇｆ 베타 쇄와 ｃ-ｍｅｔ 사이의 상호작용의 변조
WO2005007193A2 (en) 2003-07-07 2005-01-27 Vande Woude, George, F. Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
US20070036797A1 (en) 2005-06-02 2007-02-15 Galaxy Biotech, Llc Methods of treating brain tumors with antibodies
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
IL178474A (en) 2011-04-28
US20070160613A1 (en) 2007-07-12
EP1734995A1 (en) 2006-12-27
CA2563080A1 (en) 2005-11-17
BRPI0418745A (pt) 2007-12-11
CN1964738A (zh) 2007-05-16
DK1734995T3 (da) 2010-10-25
US7687063B2 (en) 2010-03-30
CA2563080C (en) 2015-01-27
US20080019966A1 (en) 2008-01-24
US20090104192A1 (en) 2009-04-23
RU2361879C2 (ru) 2009-07-20
IL178474A0 (en) 2007-02-11
EP1734995B1 (en) 2010-07-14
US7494650B2 (en) 2009-02-24
WO2005107800A1 (en) 2005-11-17
PL1734995T3 (pl) 2010-12-31
AU2004319276C1 (en) 2011-03-03
DE602004028168D1 (de) 2010-08-26
ES2346886T3 (es) 2010-10-21
ATE473760T1 (de) 2010-07-15
EP2204191A1 (en) 2010-07-07
US20040208876A1 (en) 2004-10-21
EP1734995A4 (en) 2007-04-25
CY1110783T1 (el) 2015-06-10
AU2004319276A1 (en) 2005-11-17
KR101072736B1 (ko) 2011-10-11
ZA200609407B (en) 2008-07-30
MXPA06011822A (es) 2007-03-23
PT1734995E (pt) 2010-08-18
NZ550324A (en) 2009-12-24
AU2004319276B2 (en) 2010-08-26
JP2011012067A (ja) 2011-01-20
KR20070012711A (ko) 2007-01-26
HK1094167A1 (en) 2007-03-23
NO20065227L (no) 2007-01-10
JP2007532643A (ja) 2007-11-15
SI1734995T1 (sl) 2010-09-30
JP4594381B2 (ja) 2010-12-08
RU2006140257A (ru) 2008-05-20
CR8698A (es) 2007-12-17
US20120064066A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
HRP20100521T1 (hr) Monoklonska antitijela protiv čimbenika rasta hepatocita
HRP20210393T1 (hr) Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja
TWI549968B (zh) 抗體-藥物共軛體
JP6325527B2 (ja) ヒト化ｐａｎ−ｈｅｒ抗体組成物
CN104136042B (zh) 使用抗假单胞菌Psl和PcrV结合分子的联合治疗
HRP20151019T1 (hr) PROTUTIJELA PROTIV c-MET
KR20160047567A (ko) 조작된 항-dll3 접합체 및 사용 방법
NZ712762A (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
TW201834695A (zh) 共軛生物分子、醫藥組成物及方法
EA200101064A1 (ru) Лечение раковых заболеваний путем комбинированного введения доцетаксела с рекомбинантными гуманизированными моноклональными анти-her2 антителами
JP2018534933A5 (ja)
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
HRP20160494T4 (hr) Antigen-vezujući proteini za proproteinsku konvertazu subtilizin keksin tipa 9 (pcsk9)
RU2015144287A (ru) Составы конъюгата антитело против egfr-лекарственное средство
HRP20221471T1 (hr) Protutijela anti-fgfr3 i postupci za njihovu uporabu
CN106536562A (zh) 来那度胺或泊利度胺与经抗CD38抗体灭毒的干扰素α构筑体的组合，和其用途
RU2009110102A (ru) Лечение опухолей с помощью антитела к vegf
HRP20110599T1 (hr) Antitijela protiv toksina clostridium difficile i njihove primjene
CN107001454A (zh) 新的抗mfi2抗体和使用方法
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
JP2010520290A5 (ja)
HRP20170687T1 (hr) Agensi koji iscrpljuju b-stanice, kao anti-cd20 protutijela ili njihovi fragmenti za liječenje sindroma kroničnog umora
JP2018529635A5 (ja)
JP2016094424A5 (ja)